FULL LIST

  • The $150 Bioprinter Extruder That Anyone Can Build

    The $150 Bioprinter Extruder That Anyone Can Build

    Most conversations about biofabrication focus on what the technology might eventually produce, organs, tissue implants, patient-specific grafts. Fewer focus on the practical question of who can actually access the tools to do that work. A previous paper published in HardwareX and available open-access via PubMed Central addresses that question directly, by publishing the full design…

  • NAMs, New Approach Methodologies for Drug Discovery: What It Means for the Future of Alternatives to Animal Testing and Biofabrication

    NAMs, New Approach Methodologies for Drug Discovery: What It Means for the Future of Alternatives to Animal Testing and Biofabrication

    A landmark review published in Cell by Stanford’s Joseph C. Wu and colleagues maps the rise of New Approach Methodologies, human-centric tools that are beginning to replace animal models in drug discovery, and what this shift means for organoids, bioprinting, and the broader biofabrication sector.

  • Revalia Bio Secures ~$30M Government Contract to Build the Future of Human-First Drug Development

    Revalia Bio Secures ~$30M Government Contract to Build the Future of Human-First Drug Development

    Revalia Bio, a Yale-born startup redefining drug development through real human donor tissue, has secured a landmark ~$30 million U.S. government contract—one of the largest ever awarded to a seed-stage biotechnology company. The announcement marks a turning point not only for Revalia, but for the broader movement away from animal-model drug development and toward human-first…

  • JETT: Connecting Innovators with the Joint Chem Bio Enterprise

    JETT: Connecting Innovators with the Joint Chem Bio Enterprise

    The Joint Enterprise Technology Tool (JETT) is reshaping how innovators engage with the U.S. government’s chemical and biological defense community. Designed as a direct bridge between the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) and industry, JETT makes collaboration faster, clearer, and more impactful. If you’re developing a technology that…

  • NIH Launches Nation’s First Dedicated Organoid Development Center

    NIH Launches Nation’s First Dedicated Organoid Development Center

    The National Institutes of Health (NIH) has announced the creation of the nation’s first dedicated organoid development center, marking a pivotal step in reducing reliance on animal models for biomedical research. The new Standardized Organoid Modeling (SOM) Center, located at the Frederick National Laboratory for Cancer Research, will receive $87 million over the next three…

  • MIT and Polimi Develop Low-Cost AI Monitoring System to Improve 3D Bioprinting of Engineered Tissues

    MIT and Polimi Develop Low-Cost AI Monitoring System to Improve 3D Bioprinting of Engineered Tissues

    A collaborative research team from the Massachusetts Institute of Technology (MIT) and the Polytechnic University of Milan (Polimi) has introduced a modular, printer-agnostic monitoring platform designed to enhance the quality and efficiency of 3D bioprinting for tissue engineering. This development addresses a longstanding challenge in the field: the lack of integrated process control, which often…

  • Instant Collagen, Real-Time Biofabrication: What TRACE Means for the Lab & the Market

    Instant Collagen, Real-Time Biofabrication: What TRACE Means for the Lab & the Market

    Nature Materials has just published a paper that’s turning heads across the biofabrication community. Gong et al. describe TRACE – Tunable Rapid Assembly of Collagenous Elements, a macromolecular-crowding approach that lets unmodified type I collagen gel in seconds while staying pH-neutral and fully bioactive. The article racked up 9,899 views, an Altmetric score of 39,…

  • CollPlant Expands U.S. Footprint with Strategic Hire to Lead Commercial GrowthBusiness of Biofabrication

    CollPlant Expands U.S. Footprint with Strategic Hire to Lead Commercial GrowthBusiness of Biofabrication

    CollPlant Biotechnologies (NASDAQ: CLGN), a leader in recombinant human collagen (rhCollagen) innovation, has appointed Bowman Bagley as Vice President, Commercial North America. The newly created position underscores CollPlant’s growing commitment to scaling its regenerative medicine and bioprinting platforms across the U.S. and Canadian markets. Leadership with Deep Roots in Biomaterials Bagley, an experienced executive in…

  • Tides Medical and UToledo Health Pioneer 3D Bioprinted Grafts for Chronic Wound Care

    Tides Medical and UToledo Health Pioneer 3D Bioprinted Grafts for Chronic Wound Care

    UToledo Health has become one of the first healthcare systems in the U.S. to implement 3D bioprinted grafts derived from a patient’s own fat cells in the treatment of chronic wounds. The approach marks a major advancement in regenerative medicine, offering a personalized solution for patients with wounds that have resisted conventional healing methods. A…

  • Stanford Accelerates Vascular Modeling for Organ Bioprinting

    Stanford Accelerates Vascular Modeling for Organ Bioprinting

    New algorithm offers scalable design pathway for patient-specific blood vessel networks Addressing a Core Challenge in Biofabricated Organs Stanford researchers have introduced a computational tool that could remove a major roadblock in organ bioprinting: the creation of functional, patient-specific vascular networks. Their new platform, published in Science on June 12, 2025, enables the rapid design…

Subscribe

Enter your email below to receive updates.